Michael T Marrone1, Corinne E Joshu2,3, Sarah B Peskoe2, Angelo M De Marzo4,5,3, Christopher M Heaphy4,3, Shawn E Lupold5,3, Alan K Meeker4,5,3, Elizabeth A Platz2,5,3. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; mmarron6@jhu.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. 4. Department of Pathology and. 5. Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: Given translational research challenges, multidisciplinary team science is promoted to increase the likelihood of moving from discovery to health effect. We present a case study documenting the utility of multidisciplinary team science in prostate cancer tissue biomarker validation. METHODS: We used primary data generated by a team consisting of a pathologist, cancer biologists, a biostatistician, and epidemiologists. We examined their contributions by phase of biomarker evaluation to identify when, through the practice of team science, threats to internal validity were recognized and solved. Next, we quantified the extent of bias avoided in evaluating the association of Ki67 (immunohistochemistry), stromal cell telomere length (fluorescence in situ hybridization), and microRNA (miRNA) (miR-21, miR-141, miR-221; quantitative RT-PCR) with prostate cancer risk or recurrence in nested case-control studies. RESULTS: Threats to validity were tissue storage time (Ki67, miRNA) and laboratory equipment maintenance (telomeres). Solutions were all in the data analysis phase and involved using tissue storage-time specific cutpoints and/or batch-specific cutpoints. Bias in the regression coefficient for quantiles of each biomarker ranged from 24% to 423%, and the coefficient for the test for trend ranged from 15% to 910%. The interpretation of the associations changed as follows: Ki67, null to positive; stromal cell telomere length, null to positive; miR-21 and miR-141 remained null; miR-221, weak to moderate inverse. CONCLUSIONS: In this case study, we documented the inferential benefits of multidisciplinary team science when the team's collaboration and coordination led to the identification of threats to validity and the implementation of appropriate solutions.
BACKGROUND: Given translational research challenges, multidisciplinary team science is promoted to increase the likelihood of moving from discovery to health effect. We present a case study documenting the utility of multidisciplinary team science in prostate cancer tissue biomarker validation. METHODS: We used primary data generated by a team consisting of a pathologist, cancer biologists, a biostatistician, and epidemiologists. We examined their contributions by phase of biomarker evaluation to identify when, through the practice of team science, threats to internal validity were recognized and solved. Next, we quantified the extent of bias avoided in evaluating the association of Ki67 (immunohistochemistry), stromal cell telomere length (fluorescence in situ hybridization), and microRNA (miRNA) (miR-21, miR-141, miR-221; quantitative RT-PCR) with prostate cancer risk or recurrence in nested case-control studies. RESULTS: Threats to validity were tissue storage time (Ki67, miRNA) and laboratory equipment maintenance (telomeres). Solutions were all in the data analysis phase and involved using tissue storage-time specific cutpoints and/or batch-specific cutpoints. Bias in the regression coefficient for quantiles of each biomarker ranged from 24% to 423%, and the coefficient for the test for trend ranged from 15% to 910%. The interpretation of the associations changed as follows: Ki67, null to positive; stromal cell telomere length, null to positive; miR-21 and miR-141 remained null; miR-221, weak to moderate inverse. CONCLUSIONS: In this case study, we documented the inferential benefits of multidisciplinary team science when the team's collaboration and coordination led to the identification of threats to validity and the implementation of appropriate solutions.
Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506
Authors: Antoun Toubaji; Roula Albadine; Alan K Meeker; William B Isaacs; Tamara Lotan; Michael C Haffner; Alcides Chaux; Jonathan I Epstein; Misop Han; Patrick C Walsh; Alan W Partin; Angelo M De Marzo; Elizabeth A Platz; George J Netto Journal: Mod Pathol Date: 2011-07-08 Impact factor: 7.842
Authors: Alcides Chaux; Sarah B Peskoe; Nilda Gonzalez-Roibon; Luciana Schultz; Roula Albadine; Jessica Hicks; Angelo M De Marzo; Elizabeth A Platz; George J Netto Journal: Mod Pathol Date: 2012-06-08 Impact factor: 7.842
Authors: Jeffrey T Leek; Robert B Scharpf; Héctor Corrada Bravo; David Simcha; Benjamin Langmead; W Evan Johnson; Donald Geman; Keith Baggerly; Rafael A Irizarry Journal: Nat Rev Genet Date: 2010-09-14 Impact factor: 53.242
Authors: Corinne E Joshu; Alison M Mondul; Andy Menke; Cari Meinhold; Misop Han; Elizabeth B Humphreys; Stephen J Freedland; Patrick C Walsh; Elizabeth A Platz Journal: Cancer Prev Res (Phila) Date: 2011-02-16
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2003-06-24 Impact factor: 91.245
Authors: Sarah B Peskoe; John R Barber; Qizhi Zheng; Alan K Meeker; Angelo M De Marzo; Elizabeth A Platz; Shawn E Lupold Journal: BMC Cancer Date: 2017-01-06 Impact factor: 4.430
Authors: Konrad H Stopsack; Svitlana Tyekucheva; Molin Wang; Travis A Gerke; J Bailey Vaselkiv; Kathryn L Penney; Philip W Kantoff; Stephen P Finn; Michelangelo Fiorentino; Massimo Loda; Tamara L Lotan; Giovanni Parmigiani; Lorelei A Mucci Journal: Elife Date: 2021-12-23 Impact factor: 8.140
Authors: Konrad H Stopsack; Ying Huang; Svitlana Tyekucheva; Travis A Gerke; Clyde Bango; Habiba Elfandy; Michaela Bowden; Kathryn L Penney; Thomas M Roberts; Giovanni Parmigiani; Philip W Kantoff; Lorelei A Mucci; Massimo Loda Journal: Clin Cancer Res Date: 2020-09-10 Impact factor: 12.531